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in the pathogenesis of various diseases. Numerous in vitro and
animal studies show that oxidative modification of low density
lipoprotein (LDL) is an important initial event of atherosclerosis.
Vitamin E and other antioxidants inhibit low density lipoprotein
oxidation efficiently in vitro, however, human clinical trials with
vitamin E have not yielded positive results. The mixed results for
vitamin E effect may be ascribed primarily to the two factors.
Firstly low density lipoprotein oxidation proceeds by multiple
pathways mediated not only by free radicals but also by other
non radical oxidants and vitamin E is effective only against free
radical mediated oxidation. Secondly, in contrast to animal experi 
ments, vitamin E is given at the latter stage where oxidation is no
more important. Free radicals must play causal role in patho 
genesis of atherosclerosis and vitamin E should be effective if
given at right time to right subjects.
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Introduction It is now widely accepted that free radicals and related reactive
oxygen and nitrogen species, ROS/RNS, play an important
role in the pathogenesis of various disorders and diseases, although,
like oxygen molecule, they are double edged sword and under
certain circumstances they exert important physiological functions
to protect the host from foreign compounds and to maintain
homeostasis. Many lines of evidence suggest involvement of
free radicals in the pathogenesis of various diseases and in fact
numerous observations have been reported which suggest the
correlation between the increase in free radical-mediated oxida-
tion products and the progression of diseases. One of such
examples is the oxidation of low density lipoprotein (LDL) and
atherosclerosis. Since the first proposal of the LDL oxidation
hypothesis for atherosclerosis by Steinberg and his colleagues
in 1989,(1) ample evidence has been presented supporting the
hypothesis that oxidative modification of LDL is the key initial
event for the progression of atherosclerosis.(2) Oxidized LDL
stimulates endothelial cells to produce inflammatory markers, is
involved in foam cell formation, has cytotoxic effects on endo-
thelial cells, inhibits the motility of tissue macrophages, and
inhibits nitric oxide-induced vasodilatation. It is now clear that
oxidation of LDL lipids and apolipoprotein B 100 renders LDL
pro-atherogenic(3) and furthermore high density lipoprotein (HDL)
oxidation impairs its inherent anti-atherogenic properties.(4)
Thus, it is generally accepted that oxidative modification of LDL
followed by uptake of the modified LDL by macrophages and
formation of cholesterol laden foam cells is important initial event
of atherosclerosis leading to vascular diseases.
The above evidence suggests that the antioxidants which inhibit
oxidation of LDL and HDL should be effective for prevention of
atherosclerosis and related diseases and numerous studies have
been performed to examine the beneficial effect of antioxidants.
It has been shown that the antioxidants which inhibit LDL oxida-
tion in vitro are in general, if not always, effective for prevention
of atherosclerosis in animal models. However, the results of
large scale human intervention studies have been inconsistent
and disappointing. Among the antioxidants, vitamin E has been
studied most extensively, but the results did not show consistently
positive effects as summarized in Table 1. These results have
casted doubts on the oxidation hypothesis and also the role of
antioxidants. Considering the facts that the diseases related to
atherosclerosis such as cardio- and cerebral vascular diseases are
one of the major causes of death today, the free radicals, lipo-
protein oxidation, and vitamin E are important issues that should
be addressed in more detail.
This brief review focuses on the LDL lipid oxidation and
effect of vitamin E as an antioxidant against LDL oxidation
atherosclerosis and discusses possible complications related to
them.
LDL Oxidation
LDL particle contains several hundred molecules each of phos-
pholipids, cholesteryl esters, and triglycerides together with free
cholesterol. LDL oxidation proceeds by multiple mechanisms
induced by different oxidants.(3) LDL may be oxidized within
artery wall and also in peripheral sites of inflammation. Lipids,
above all polyunsaturated fatty acids (PUFAs) are quite vulnerable
to free radical attack and readily oxidized to give versatile products
including aldehydes, which react with lysines and tyrosines in
apo-lipoprotein B-100 resulting in their modification and func-
tional loss. A minimally oxidized LDL, which is still recognized
by LDL receptors but not by a ligand for scavenger receptors,
exerts pro-atherogenic effects.(5) The oxidation of LDL lipids
has been studied extensively and the products of phospholipids
and cholesteryl esters have been studied in detail for their levels
and roles in atherosclerosis.(6) Polycyclic ring and side chain of
cholesterol are also an important substrate and oxidized to give
various products named oxysterols.(7) One important issue is
that lipids are oxidized by several types of oxidants by distinct
mechanisms and the capacity of antioxidants depends on the
oxidants. Therefore, it is important to analyze lipid oxidation
products from which the oxidants can be specified and antioxidant
efficacy may be assessed.
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Arachidonates, esters of 5,8,11,14-eicosatetraenoic acid, are
one of the major PUFAs in vivo and their oxidation gives hydroxy-
eicosatetraenoates, HETE, as major lipid oxidation product found
in human plasma. Various isomers of HETE are produced by
different oxidants as summarized in Table 2, which shows that 5-,
12-, and 15-HETE are formed by either free radicals, lipoxy-
genase, cytochrome P450 or singlet oxygen. α-Tocopherol, a
major isoform of vitamin E in vivo, is effective only against free
radical-mediated oxidation and it is not a potent antioxidant
against oxidation induced by lipoxygenase, cytochrome P450,
nor singlet oxygen.
The oxidants responsible for LDL oxidation in vivo have been
the subject of extensive studies and arguments. Various com-
pounds have been shown to induce LDL oxidative modification
to such a form observed in atherosclerotic lesions. Metals such as
iron and copper may be a potent candidate, although they are
sequestered by proteins in vivo. Hemoglobin (Hb) and myoglobin
are known to induce LDL oxidation. Hemoglobin may be leaked
from damaged erythrocytes, especially in the vascular regions
with turbulent flow, or in hemodialysis patients. Hemoglobin is
sequestered by haptoglobin (Hp) which exists as a homodimer,
whose monomer could be one of the allelic variants, Hp1 or Hp2.
Hp2 variant is less effective in preventing oxidation than Hp1 and
interestingly subjects with the Hp2-2 phenotype have higher risk
for CVD than those with Hp1-1 or Hp1-2 variants.(8) The patients
of Wilson disease have abnormally low levels of ceruloplasmin
which bind copper and copper accumulated in the liver may cause
oxidative stress.(9) The redox active transition metal ions such as
iron and copper contribute to the formation of free radicals and in
the initiation of LDL oxidation.
It has been observed that LDL is oxidized when incubated
with several types of cells such as endothelial cells, smooth
muscle cells, neutrophils, and macrophages. Various enzymes
may contribute in the oxidation such as myeloperoxidase, lipoxy-
genase, NADPH oxidases and nitric oxide synthases.
Myeloperoxidase (MPO), a heme enzyme released by activated
neutrophils and monocyte/macrophages at sites of inflammation,
has been implicated in the oxidation of LDL and HDL.(4) MPO
together with hydrogen peroxide and chloride ion produces
hypochlorite, which is a strong oxidant and oxidizes proteins and
lipids by radical and non-radical mechanisms. Chlorohydrins are
specific product of hypochlorite mediated non-radical oxidation
and it was found that lysophosphatidylcholine chlorohydrins
were elevated over 60 fold in human atherosclerotic lesions,(10)
although hypochlorite reacts with protein components more
rapidly than with lipids.(11) There is now ample evidence showing
that MPO modifies both LDL and HDL into pro-atherosclerotic
forms. Importantly, vitamin E is not a potent inhibitor of hypo-
chlorite mediated oxidation.
Lipoxygenase, LOX, is another important oxidant. Above all,
15-LOX is capable oxidizing arachidonate and linoleate of pho-
pholipids and cholesteryl esters within LDL particles directly to
give 15-hydroperoxy-eicosatetraenoic acid (15-HpETE) and 13-
hydroperoxy-octadecadienoic acid (13-HpODE) respectively. In
contrast to free radical oxidation which gives random, racemic
products, the oxidation by 15-LOX gives regio-, stereo-, and
enantio-specific products, which are in fact found in human
atherosclerotic lesions. Kuhn and his colleagues found that in
young human lesions the hydroxyl-linoleic acid/linoleic acid
ratio was much smaller than that in advanced lesions and that the
ratio of S/R of 13- hydroxy-octadecadienoic acid (13-HODE) was
significantly higher than 1, suggesting a contribution of 15-LOX
especially for early atherogenesis.(12)
As described above, LDL may be oxidized in vivo by different
oxidants by either free radical or non-radical mechanisms. Specific
products of lipid oxidation for different oxidants are summarized
in Table 3. Cholesterol is oxidized also by different oxidants to
give specific products. The trans, trans form of HODE and HETE
are specific products of free radical oxidation and 9- and 13-
trans,trans-HODE are convenient marker for free radical oxidation
of linoleates. F2-isoprostanes and F4-neuroprostanes formed by
free radial oxidation of arachidonates and docosahexanoates
respectively are now accepted as most reliable biomarker of lipid
oxidation  in vivo. 7β-hydroxycholesterol and 7-ketocholesterol
are formed primarily by free radical oxidation of cholesterol.
An increase in lipid oxidation products in atherosclerosis
patients and experimental animals has been observed in many
studies(13) and references cited therein. It is known that the
oxidative modification of LDL increases electronegativity of
LDL particles. We have confirmed that the levels of trans,trans-
HODE, 8-isoprostane(8-isoP), and 7β-hydroxycholesterol, specific
products of free radical oxidation, increased with an increase in
LDL electronegativity of human LDL, both in absolute concentra-
tion and in the ratio relative to respective parent substrate.(14)
HDL Oxidation
HDL is inherently capable of exerting anti-atherogenic effect
by metabolizing and transporting lipid oxidation products as
well as cholesterol from the cells to the liver by virtue of paraox-
onase-1 (PON-1), lecithin-cholesterol acyltransferase (LCAT),
Table 1. Results of human clinical trials on the effects of vitamin E
against atherosclerosis and related diseases
ASAP: Antioxidant supplementation in atherosclerosis prevention
study; ATBC: The alpha tocopherol, beta carotene cancer prevention
study; CHAOS: Cambridge heart antioxidant study; CLAS: Cholesterol
lowering atherosclerosis study; Fang et al.;(33) GISSI: Gruppo Italiano
per lo studio della sopravvivenz nell infarto miocardico; HATS: HDL
atherosclerosis treatment study; HOPE: The heart outcomes prevention
evaluation study; HPS: Heart protection study; ICARE: Israel cardio 
vascular events reduction with vitamin E study; IEISS: Indian experiment
of infarct survival 3; MVP: Multivitamin prevention study; PHS II:
Physicians’ Health Study II; PPP: Primary prevention project; SPACE:
Secondary prevention with antioxidants of cardiovascular disease in
endstage renal disease; SUVIMAX: SUpplémentation en VItamines
et Minéraux AntioXydants Study; TAAS: Transplant associated arterio 
sclerosis study; VEAPS: Vitamin E atherosclerosis prevention study;
WACS: Women’s antioxidant cardiovascular study; WAVE: Women’s
angiographic vitamin and estrogen trial.
YES NO
CHAOS (1996) MVP (1997)
CLAS (1996) ATBC (1997, 1998)
IEISS (1996) GISSI (1999)
ASAP (2000) HOPE (2000)
SPACE (2000) PPP (2000)
TAAS (2002) HPS (2002)
WACS (2007) VEAPS (2002)
ICARE (2008) SUVIMAX (2004)
HATS (2004)
WAVE (2006)
PHS II (2008)
Table 2. Hydroxyeicosatetraenoic acid (HETE) isomers from oxidation of
arachidonic acid: 5,8,11,14 eicosatetraenoic acid
Isomers
Regio Stereo Enantio
Free radical 5, 8, 9, 11, 12, 15 ZE, EE R = S
Lipoxygenase 5, 12, 15 ZE R or S
Cytochrome P450 5, 8, 9, 11, 12, 15, 19, 20 ZE R or S
Singlet oxygen 5, 6, 8, 9, 11, 12, 14, 15 ZE J. Clin. Biochem. Nutr. | January 2011 | vol. 48 | no. 1 | 5
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phospholipase A2, and platelet-activating factor acetylhydrolase
(PAF-AH).(15,16) The oxidative modification of HDL impairs the
“reverse cholesterol transport” ability of apoA-I and also anti-
inflammatory function of HDL.(17) It is assumed that HDL is
oxidized by substantially the same oxidants and mechanisms as
LDL. It has been found that HDL is a major carrier of lipid
hydroperoxides(18) and isoprostanes.(19) The higher lipid oxidation
products in HDL than in LDL may be due to higher activity of
PAF-AH in LDL which hydrolyses esterified oxidation products
from phospholipids.
Effect of Vitamin E against LDL Oxidation and Athero 
sclerosis
Numerous studies show that vitamin E and related radical
scavenging antioxidants inhibit LDL oxidation efficiently in vitro,
especially together with vitamin C. The dynamics of antioxidant
action of vitamin E in LDL particle has been studied in detail.(20)
Furthermore, vitamin E and related synthetic antioxidant such
as 2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran
(BO-653) suppressed atherosclerosis development in animal
models.(21) These results strongly suggest that antioxidants should
exert protective and therapeutic effects against atherosclerosis and
related diseases and supplementation of antioxidants, particularly
vitamin E, received much attention.
Effects of Vitamin E in Humans
Many large scale epidemiologic studies such as WHO/MONICA
study,(22) Health Professionals’ follow-up study,(23) Nurses’ Health
Study,(24) and EVA study(25) supported the beneficial effect of
vitamin E against atherosclerosis and cardiovascular diseases.
However, in contrast to this expectation, the results of large
scale randomized clinical intervention studies of vitamin E were
disappointing. Moreover, some meta-analyses showed that vitamin
E supplementation may increase mortality. These results have
raised much arguments and criticisms.(26–28) The choice of proper
subjects, antioxidant, and dose and duration of supplementation
has been argued as important factors that determine the outcome.
The importance of biomarker measurement, patient compliance,
and data interpretation has been pointed out also.
Two points should be emphasized here as critical factors which
Table 3. Specific oxidation products of linoleates, arachidonates, and cholesterol for different oxidants
COX: cyclooxygenase; HETE: hydroxy eicosatetraenoic acid; H(p)ETE: hydroperoxy eicosatetraenoic acid; H(p)ODE: hy 
droperoxy octadecadienoic acid; KCh: ketocholesterol; LOX: Lipoxygenase; MPO: Myeloperoxidase; PGD: prostaglandin
D; PGE: prostaglandin E; PGF: prostaglandin F; PGH2: prostaglandin H2; TX: thromboxane; OOHCh: hydroperoxycholes 
terol; OHCh: hydroxycholesterol
Linoleate Arachidonate Cholesterol
Free racdical (LO ) 9 ,13 EE H(p)ODE F2 isoprostane 7α OHCh, 7 KCh
NO2 nitro linoleates NO2 Ch
1O2 10 ,12 ZE H(p)ODE 5 OOHCh, secosterol
Ozone secosterol
LOX 13(S) H(p)ODE, S/R>>1 5 ,12,15 H(p)ETE
COX PGH2, PGD, PGE, PGF, TX
CYP450 19,20 HETE 4α ,24(S) ,27 OHCh
MPO, HOCl chlorohydrin chlorohydrins, secosterol
2 ·
Table 4. Biomarkers of oxidative stress
HETE: hydroxy eicosatetraenoic acid; HODE: hydroxy octadecadienoic acid; LysoPC: lysophosphatidylcholine; Oxidized
LDL: oxidized low density lipoprotein; TBARS: thiobarbituric acid reactive substances
Lipid Protein DNA
Ethane and pentane Protein carbonyl Comet assay
in exhaled gas Hydroperoxide Thymine glycol
TBARS Nitro , chloro , bromo amino acid 2 , 8 Hydroxyadenine
Conjugated diene Disulfide  SS  8 Hydroxyguanine
Hydroperoxide  SOH,  SOOH,  SOOOH 8 Nitro , chloro , bromo guanine
Aldehydes Aldehyde modified protein Lipid peroxidation product modified
Ketone Hydroperoxide modified protein DNA bases
Isoprostane Crosslinked protein
Neuroprostane Dityrosine
Isofuran Albumin dimer
Neurofuran Advanced oxidation products
HODE Creatol
HETE Myeloperoxidase
Lyso PC Lipofuscin
Nitrofatty acids Cleavage products
Chlorohydrins
Oxidized LDL
Oxysterolsdoi: 10.3164/jcbn.11 007FR
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determine the efficacy of vitamin E. Firstly, as mentioned above,
oxidative modification of LDL and HDL proceeds by different
oxidants by different mechanisms, and vitamin E is effective
against free radical mediated oxidation, but not against oxidation
induced by lipoxygenase and hypohalite. An increase in the levels
of oxidation products produced not only by free radical oxidation
but also by lipoxygenase and hypochlorite has been observed and
the relative importance of these different mechanisms may vary,
suggesting that the relative importance of vitamin E may also vary
according to time and circumstance.
Secondly, atherosclerosis is a chronic disease and its onset,
that is, the oxidative modification of LDL may have taken place
decades before the symptoms appear. The major difference
between human trials and animal experiments is that, in general,
human trials start often after the onset of oxidative modification of
LDL at the age of 50 or above, whereas in animal studies vitamin
E or other antioxidant is given usually at the same time as the onset
of oxidative stress (Fig. 1). It may be unrealistic to expect that a
few years of antioxidant supplementation can turn around the ef-
fects of oxidative stress on endothelium which lasted more than 30
years. In contrast to human trials, the animal studies are performed
under the same lifestyle with the same diet, which may yield more
consistent outcome than human trials.
Biomarkers
It has been pointed out that the measurement of biomarkers
for oxidative stress and antioxidant level in the subjects is
important for the evaluation of antioxidant supplementation.
Various biomarkers have been used for assessment of oxidative
stress in vivo (Table 4). The levels and products of antioxidants
have been used also as a biomarker of oxidative stress.(29) Plasma
and urine have been used often as a convenient, non-invasive
specimen, but these are global measurements and it is difficult
to specify where the oxidation takes place: the oxidation may be
occurring at sites relating to atherogenesis or anywhere in the
body. It should be considered also that the biomarkers listed in
Table 4 are surrogate markers which may give different effect
from that based on clinically relevant outcome.
It is important to develop new tools and methods to prove if
vitamin E is effective in the prevention of atherosclerosis in
humans. Non-invasive imaging techniques appear to be promising.
There is increasing evidence that (18)F-fluorodeoxyglucose
(FDG)—positron emission tomography (PET) imaging can be
useful for non-invasive measurement of atherosclerotic plaque
inflammation in humans.(30) Radio isotope labeled anti-lectin like
oxidized LDL receptor 1 (LOX-1) monoclonal IgG has been used
as potential agent for imaging atherosclerotic.(31) Furthermore,
CT/PET imaging using radioisotope-labeled monoclonal antibody
against oxidized LDL or related oxidation products can be a
powerful tool for monitoring progression of atherosclerosis and
assessment of the antioxidant effects.(32)
Conclusion
Free radicals must play important causal role in the patho-
genesis of some diseases and antioxidants such as vitamin E must
be beneficial for prevention and/or treatment of such diseases
when used at right time and to right subjects under oxidative
stress.
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